Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). First-quarter 2026 financial results announced May 7, 2026.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- First-quarter 2026 financial results announced May 7, 2026
- Full results, operating metrics, and management commentary in Exhibit 99.1
- Furnished under Item 2.02, indicating earnings information rather than a new contractual obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.